Design Therapeutics (Design Therapeutics) EV-to-EBIT : 0.85 (As of Apr. 27, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Design Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Design Therapeutics's Enterprise Value is $-66.33 Mil. Design Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-78.19 Mil. Therefore, Design Therapeutics's EV-to-EBIT for today is 0.85.

The historical rank and industry rank for Design Therapeutics's EV-to-EBIT or its related term are showing as below:

DSGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -55.55 Med: -17.94 Max: 5.35
Current: 0.85

During the past 5 years, the highest EV-to-EBIT of Design Therapeutics was 5.35. The lowest was -55.55. And the median was -17.94.

DSGN's EV-to-EBIT is ranked better than
68.62% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs DSGN: 0.85

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Design Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-129.09 Mil. Design Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-78.19 Mil. Design Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 60.57%.

Design Therapeutics EV-to-EBIT Historical Data

The historical data trend for Design Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Design Therapeutics EV-to-EBIT Chart

Design Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-22.51

-3.65

1.65

Design Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial												-3.65	-0.14	-0.64	1.89	1.65

Competitive Comparison of Design Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Design Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Design Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Design Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Design Therapeutics's EV-to-EBIT falls into.

Design Therapeutics EV-to-EBIT Calculation

Design Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-66.330	/	-78.19
	=	0.85

Design Therapeutics's current Enterprise Value is $-66.33 Mil.
Design Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.19 Mil.

Design Therapeutics (NAS:DSGN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Design Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-78.19	/	-129.09296
	=	60.57 %

Design Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-129.09 Mil.
Design Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.19 Mil.

Design Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Design Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Design Therapeutics (Design Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Design Therapeutics Inc (NAS:DSGN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011

Website

https://www.designtx.com

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

Executives

Rodney W Lappe	director	C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Deepa Prasad	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265
Arsani William	director	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Joao Md Siffert	director, officer: President and CEO	20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Simeon George	director, 10 percent owner	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Stella Xu	director, 10 percent owner	C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Julie Burgess	officer: Chief Accounting Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Dawn Giangiulio	officer: Principal Accounting Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Heather Behanna	director	C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Pratik Shah	director, officer: Executive Chairperson	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Sean Jeffries	officer: Chief Operating Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Justin Thacker	officer: Vice President, Finance	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Aseem Z. Ansari	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011